De følgende lægemiddelrelaterede bivirkninger rapporteredes under kliniske undersøgelser af CTCL - patienter (N=109), som behandledes med den anbefalede indledende dosis på 300 mg/ m²/ dag.
The following Targretin-related adverse reactions were reported during clinical studies in patients with CTCL (N=109) treated at the recommended initial dose of 300 mg/ m2/ day.